Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy

Fig. 4

Survival curves based on the four-immune factor immunoprofile system. a The expression of PD-L1 in tumor cells and the infiltration of CD8+/Foxp3+/CD33+ cells have separated all patients into different risk subgroups using a value of 3.25. b-e Same-stage patients could be separated into different risk subgroups by the immunoprofile. f ROC analyses of 5-year survival rate based on the immunoprofile system and TNM stage for esophageal squamous cell carcinoma patients (n = 150). AUC, area under the curve

Back to article page